Clinical Trial Update: A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Rebamipide Liquid for preventing chemoradiotherapy-induced oral mucositis in head and neck cancer patients has completed with posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Rebamipide Liquid (rebamipide)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-04-06